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Purpose: This meta-analysis aims to summarize 12-month best-corrected visual acuity 
(BCVA) outcomes in response to anti-vascular endothelial growth factor (VEGF) therapy 
and dexamethasone implant for the treatment of diabetic macular edema (DME) and to 
identify factors affecting treatment response using evidence generated from meta- 
regression.
Methods: A systematic review of electronic databases was conducted to identify rando-
mized controlled trials (RCTs) and real-life/observational studies that reported 12-month 
changes in BCVA in patients with DME on anti-VEGF or dexamethasone implant 
treatment in monotherapy. Study factors that were analyzed are baseline patient char-
acteristics, study type, drug employed, number of injections and 12-month change in 
BCVA. Data were pooled in a random-effects meta-analysis with BCVA change as the 
main outcome. Meta-regression was conducted to assess the impact of multiple 
covariates.
Results: One-hundred-five heterogeneous study populations (45,032 eyes) were identified 
and included in the analysis. The use of anti-VEGFs and dexamethasone implant induced an 
overall increase of +8.13 ETDRS letters in BCVA at 12 months of follow-up. Meta- 
regression provided evidence that mean BCVA change using anti-VEGFs was not statisti-
cally higher for RCTs (p=0.35) compared to observational studies. Dexamethasone implant 
showed a trend for better results in observational studies over RCTs. Populations following 
a fixed aflibercept regimen performed better than those following a reactive treatment regi-
men. Mean BCVA gain was higher in younger populations (p<0.001), with lower baseline 
BCVA (p<0.0001) and longer diabetes duration (p<0.0001), receiving a higher number of 
injections (p<0.0001).
Conclusion: Intravitreal therapy with anti-VEGFs or dexamethasone implant produces 
a significant improvement in BCVA at 12 months in patients with DME. Meta-regression 
identified the modifiable covariates that can be targeted in order to maximize functional 
results.
Keywords: aflibercept, anti-VEGF, bevacizumab, dexamethasone, diabetic macular edema, 
ranibizumab
Introduction
Diabetic macular edema (DME) is a sight-threatening disease and a major cause 
of blindness among people in working age. It affects about 7 million patients 
with diabetic retinopathy (DR).1 The prevalence of DME increases with duration 
of disease and stage of DR, approaching 30% in adults who have had diabetes 
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for more than 20 years and 71% of those with prolif-
erative diabetic retinopathy.2,3
Grid and focal laser photocoagulation used to be the 
only evidence-based treatment modality to preserve vision 
in patients with DME.4 However, several decades of basic 
science research have revealed a growing and complex 
array of vascular permeability factors, such as vascular 
endothelial growth factor (VEGF), and proinflammatory 
mediators, providing the scaffold for identifying potential 
therapeutic targets.5 The introduction of intravitreal treat-
ments has completely revolutionized the management of 
DME during the last decade. Anti-VEGF molecules, such 
as ranibizumab and aflibercept are commonly used as first- 
line therapy, while bevacizumab, a monoclonal antibody 
approved for the treatment of different types of cancer, is 
often employed in an off-label fashion in many 
countries.6–11 An innovative, controlled-release, bioerod-
ible dexamethasone implant was licensed for the treatment 
of DME in 2014.12 The current body of evidence on the 
efficacy and safety of anti-VEGF agents and dexametha-
sone implant is broad and steadily growing as randomized 
controlled trials (RCTs) and real-life/observational studies 
are completed. As clinical experiences have accumulated, 
it has become necessary to synthesize the updated results 
to provide information that can be useful in clinical prac-
tice. Therefore, we performed a systematic review and 
a meta-analysis of published RCTs and observational/real- 
life studies to sum up available evidence and to quantify 
the efficacy of intravitreal anti-VEGFs and dexamethasone 
implant for the treatment of DME. In addition, we aimed 
to identify patient and study factors that may affect the 
reporting of outcomes through a meta-regression model.
Specifically, the aim of this study is to respond to the 
following questions:
1. Is there a difference between results from RCTs and 
real-life/observational studies?
2. Is there a difference between results from RCTs and 
real-life/observational studies when analyzing drug 
classes?
3. Considering both RCTs and real-life/observational 
studies, does the treatment regimen influence the 
outcome when using anti-VEGFs?
4. Does the treatment regimen employed in real-life 
/observational studies influence the outcome when 
using anti-VEGFs?
5. If fixed regimen produces better outcomes, is this 
true for all anti-VEGFs?
6. Does the frequency of treatments influence the out-
comes when using anti-VEGFs?
7. If frequency of injections influences the outcome, is 
this true for all anti-VEGFs?
8. Considering both RCTs and real-life/observational 
studies, which drug shows more favorable results in 
literature?
9. Which drug shows more favorable outcomes in 
literature, when considering only real-life/observa-
tional studies?
10. What are the baseline characteristics that signifi-
cantly influence visual outcomes in real-life?
Materials and Methods
A multistage approach, including a systematic literature 
review (SLR), a meta-analysis, and a meta-regression, was 
used to determine the efficacy/effectiveness of intravitreal 
therapy in patients with DME.
Systematic Literature Review
A SLR of published studies including patients with DME 
receiving intravitreal ranibizumab, aflibercept, bevacizu-
mab or dexamethasone implant with one-year follow-up 
was conducted. A systematic search of the PubMed, 
Medline, Embase, and Cochrane Library databases for 
relevant literature published was performed until May 15, 
2020. The search strategy was centered on the amalgama-
tion of medical subject headings and the keywords: “dia-
betic macular edema”, “macular oedema”, “macular 
edema”, “anti-VEGF”, “DME”, “DMO”, “aflibercept”, 
“bevacizumab”, “ranibizumab”, “dexamethasone”.
All search hits were imported into a spreadsheet, and 
data from eligible abstracts and full-text studies were 
extracted and selected on the basis of relevant populations, 
interventions, comparators, outcomes, and study design. 
The data extraction template was built using the Meta- 
Analyses and Systematic Reviews of Observational 
Studies guidelines, and the reporting of the SLR followed 
the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines.13 Screening of title, 
abstract, and full text was performed using PRISMA 
guidelines. RCTs, and real-world prospective and retro-
spective clinical studies were included. Data from eligible 
articles meeting inclusion criteria were extracted indepen-
dently by two authors (VSa and VSo) and disagreements 
were resolved by consensus. The risk of bias was evalu-
ated both qualitatively and quantitatively using the Downs 
and Black checklist. The same two authors evaluated data 
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and categorized articles obtained from the literature search 
to assess quality.
Meta-Analysis
A meta-analysis of the data identified from the SLR was 
undertaken. Inclusion criteria for the meta-analysis were 
studies enrolling DME patients who received monother-
apy with ranibizumab, aflibercept, bevacizumab or dex-
amethasone implant, reported 52-week (±4 weeks) 
effectiveness outcomes. The primary objective of the 
meta-analysis was to derive a pooled estimate for effec-
tiveness (defined as best-corrected visual acuity (BCVA) 
change from baseline to week 52 in Early Treatment 
Diabetic Retinopathy Study (ETDRS) letters). When 
necessary, variables of interest were converted: 
logMAR and decimal to ETDRS letters. Fixed-effects 
and random-effects models were used to produce esti-
mates. Heterogeneity was assessed using the I2 statistic. 
Publication bias was evaluated by Egger’s linear regres-
sion and visualized with funnel plots.
Meta-Regression and Moderators 
Selection
A meta-regression analysis was undertaken. Primary 
moderators were pre-selected based on existing evidence. 
Moderators included in the meta-regression were age at 
baseline, diabetes duration, baseline BCVA, baseline cen-
tral retinal thickness (CRT), study type (RCT, real-life 
/observational study), treatment regimen, number of 
injections, and drug/drug class. The outcome variable 
assessed was mean BCVA change in ETDRS letters at 
52 weeks (±4 weeks).
Compliance with Ethics Guidelines
This study is based on previously conducted studies 
and does not involve any new studies of human parti-
cipants. This study did not require ethical approval as 




The flowchart of the selection process is reported in 
Figure 1.
Our search resulted in 107 study titles that were 
screened for eligibility criteria.
Thirty-three papers were excluded based on failure to 
meet inclusion criteria, and 2 studies were ruled out on 
the basis of missing statistical parameters. The final 
analysis contained 105 heterogeneous patient popula-
tions described by 72 studies.14–80 The enrolled papers 
spanned 1 decade.
Study Characteristics
Characteristics of the 72 studies included for statistical 
analysis are shown in Table 1. All studies were composed 
of multiple heterogeneous study groups, which were trea-
ted as individual study populations in this analysis. 
A majority of studies were real-life/observational, which 
was defined as single-arm interventional designs and 
retrospective chart reviews. One-hundred-five heteroge-
neous study populations were identified. The size of the 
study populations varied widely, ranging from 6 to 
15,273 eyes, with a total of 45,032 eyes included. Mean 
baseline BCVA ranged from 31 to 85 ETDRS letters. 
Mean baseline CRT ranged from 306 to 701 μm. Seventy- 
two studies were individually scored for their methodo-
logical quality using the Downs and Black checklist. 
Scores for methodological quality ranged from 14 to 20, 
with an overall mean score of 17.1. Overall, reduced 
quality across studies can be attributed to inadequate 
reporting of blinding, loss to follow-up and characteris-
tics of patients lost to follow-up, randomization, adjust-
ment for confounding variables and estimates of random 
variability. Of the 72 studies included, 21 were rando-
mized clinical trials, 22 were prospective cohort studies, 
and 29 were retrospective cohort studies.
Meta-Analysis
We found a high heterogeneity among included studies in 
this meta-analysis (I2 =96.542%; p < 0.001) and a random- 
effects model was chosen. A leave-one-out sensitivity 
analysis showed that none of the single studies had 
a significant effect on overall effect size. The meta- 
analysis showed an overall increase in BCVA at 12 months 
of +8.13 ETDRS letters (95% CI: 7.26–9.00) (Forest plot 
is available as Figure S1).
Meta-Regression Analyses
Robust effect modification was found for several modera-
tors. We employed a meta-regression approach to provide 
answers to clinically significant questions.
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Figure 1 Flowchart of studies meeting inclusion and exclusion criteria from literature review.
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Is There a Difference Between Results from RCTs 
and Real-Life/Observational Studies?
Regression of difference in means on study type was not 
statistically significant (p=0.55), showing a coefficient of 
+0.55 ETDRS letters favouring RCTs over real-life/obser-
vational studies (CI 95%: −2.4; +1.3).
Is There a Difference Between Results from RCTs 
and Real-Life/Observational Studies When Analyzing 
Drug Classes?
Regression of difference in means on study type for 
each anti-VEGF was not statistically significant 
(p=0.35), showing a coefficient of +0.9 ETDRS letters 
favouring RCTs over real-life/observational studies (CI 
95%: −2.7; +1.0). The same analysis performed for 
dexamethasone implant showed a trend for better 
results in real-life/observational studies over RCTs 
(coefficient +1.8 ETDRS letters; CI 95%: −3.7; 
+7.3; p=0.5).
Considering Both RCTs and Real-Life/Observational 
Studies, Does the Treatment Regimen Influence the 
Outcome When Using Anti-VEGFs?
Regression of difference in means on regimen was statistically 
significant, favouring fixed regimen over pro-re-nata (PRN) 
regimen (coefficient +2.4 ETDRS letters; CI 95%: +0.6; +4.1; 
p=0.009), and treat and extend regimen (coefficient +3.6 
ETDRS letters; CI 95%: +0.1; +7.2; p=0.043).
Does the Treatment Regimen Employed in Real-Life/ 
Observational Studies Influence the Outcome When 
Using Anti-VEGFs?
When considering only real-life/observational studies, 
regression of difference in means on regimen was not 
statistically significant. A slight trend towards better 
results with fixed regimen over PRN regimen (coefficient 
+0.4 ETDRS letters; CI 95%: −3.0; +3.9; p=0.8), and treat 
and extend regimen (coefficient +2.3 ETDRS letters; CI 
95%: −3.2; +7.6; p=0.4) was observed.
Fixed Regimen Produces Better Outcomes: Is This 
True for All Anti-VEGFs?
In ranibizumab-treated patients a trend towards better 
results for fixed regimen over PRN regimen (coefficient 
+0.7 ETDRS letters; CI 95%: −2.2; +3.7; p=0.6), and treat 
and extend regimen (coefficient +2.1 ETDRS letters; CI 
95%: −3.2; +7.6; p=0.4) was observed. Similarly, afliber-
cept-treated populations showed better results in studies 
employing fixed regimen over PRN regimen (coefficient 
+1.8 ETDRS letters; CI 95%: −1.3; +4.8; p=0.2), and treat 
and extend regimen (coefficient +4.5 ETDRS letters; CI 
95%: −0.4; +9.4; p=0.07). In bevacizumab-treated popula-
tions, regression of difference in means on regimen was 
not significantly different between fixed regimen and PRN 
regimen (coefficient +3.5 ETDRS letters; CI 95%: −0.8; 
+7.9; p=0.1).
Does the Frequency of Treatments Influence the 
Outcomes When Using Anti-VEGFs?
Regression of difference in means on mean number of 
injections was highly statistically significant (coefficient 
+0.88 ETDRS letters; CI 95%: +0.57; +1.19; p<0.0001).
Frequency of Injections Influences the Outcome: Is 
This True for All Anti-VEGFs?
When considering all anti-VEGF agents, regression of 
difference in means on mean number of injections was 
highly statistically significant (coefficient +0.88 ETDRS 
letters; CI 95%: +0.56; +1.20; p<0.0001). For ranibizumab 
the coefficient is +1.08 ETDRS letters (CI 95%: +0.57; 
+1.59; p<0.0001). For bevacizumab the coefficient is 
+0.99 ETDRS letters (CI 95%: +0.56; +1.42; p<0.0001). 
Regression of difference in means on mean number of 
injections was not statistically significant for aflibercept 
Table 1 Study Characteristics
Study Type RCT Observational/Real-Life Studies Prospective Studies Retrospective Studies
Eyes (populations) 5404 (37) 39,628 (68) 5828 (61) 39,204 (44)
Drug Ranibizumab Aflibercept Bevacizumab Dexamethasone Implant
Eyes (populations) 12,322 (43) 10,767 (30) 19,067 (14) 2876 (18)
Regimen Fixed Pro-re-nata Treat and Extend
Eyes (populations) 3831 (32) 12,210 (63) 333 (7)
Abbreviation: RCT, randomized controlled trial.
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(coefficient +0.40 ETDRS letters; CI 95%: −0.22; +1.02; 
p=0.21).
Considering Both RCTs and Real-Life/Observational 
Studies, Which Drug Shows More Favorable Results 
in Literature?
Regression of difference in means on drug shows that the 
studies employing aflibercept reported significantly super-
ior results over bevacizumab (coefficient +3.01 ETDRS 
letters; CI 95%: +0.10; +5.92; p=0.04), and dexametha-
sone implant (coefficient +3.95 ETDRS letters; CI 95%: 
+1.25; +6.65; p<0.01). The comparison with ranibizumab 
was not statistically significant (coefficient +2.01 ETDRS 
letters; CI 95%: −0.12; +4.15; p=0.06).
Which Drug Shows More Favorable Outcomes in 
Literature, When Considering Only Real-Life/ 
Observational Studies?
Regression of difference in means on drug shows that the 
real-life/observational studies employing aflibercept 
reported not significantly different results over ranibizu-
mab (coefficient +2.15 ETDRS letters; CI 95%: −1.22; 
+5.52; p=0.21), bevacizumab (coefficient +3.50 ETDRS 
letters; CI 95%: −0.57; +7.57; p=0.09), and dexametha-
sone implant (coefficient +3.56 ETDRS letters; CI 95%: 
−0.48; +7.61; p=0.08).
What are the Baseline Characteristics That 
Significantly Influence Visual Outcomes in Real-Life?
Regression of difference in means was significant on age 
(coefficient −0.54 ETDRS letters; CI 95%: −0.85; −0.23; 
p<0.001), diabetes duration (coefficient +0.98 ETDRS let-
ters; CI 95%: +0.54; +1.43; p<0.0001), baseline BCVA 
(coefficient −0.32 ETDRS letters; CI 95%: −0.46; −0.18; 
p<0.0001). Regression of difference in means on baseline 
CRT was not statistically significant (coefficient +0.31 
ETDRS letters; CI 95%: −0.33; +0.94; p=0.34).
Publication Bias and Sensitivity Analysis
Visual inspection of funnel plots suggested an asymmetry 
in the meta-analysis. The presence of publication bias was 
also indicated by Egger’s linear regression (intercept = 
1.89, p=0.03), but not by Begg’s rank correlation test 
(Kendall’s τ=0.07, p= 0.26). After adjustment of effect 
size for potential publication bias using the trim-and-fill 
correction, missing studies were imputed in the funnel 
plot, resulting in lower, albeit still highly significant esti-
mate of pooled mean difference (adjusted = +4.7 ETDRS 
letters; CI 95%: +3.7; +5.7; p<0.0001). Meta-analysis 
techniques “one-study-removed”, used in the search for 
heterogeneity sources, and ‘cumulative meta-analysis’ (in 
inverted order of sample size), to assess the potential 
impact of a small-study effect, both showed negative 
results.
A sensitivity analysis in which studies were restricted 
to those published between 2010–2016 (41 populations, 
difference in means 8.391 CI95% 7.115–9.667), and stu-
dies published between 2017–2020 (64 populations, dif-
ference in means 7.975 CI95% 6.791–9.160) was 
performed. The results did not differ from the overall 
analysis.
Discussion
DME has long been recognized as a leading cause of 
vision loss in patients with diabetes. Extensive research 
has been underway for decades to understand the precise 
pathogenesis and potential treatment modalities to 
improve, stabilize and prevent DME.5 This study was 
performed to summarize the clinical evidence from 
RCTs and real-life/observational studies on visual out-
comes of intravitreal pharmacologic approaches in the 
management of DME, obtaining a pooled estimate for 
visual acuity change from baseline to week 52. The cur-
rent meta-analysis, consisting of 45,032 eyes, is the lar-
gest and most comprehensive investigation to date that 
seeks to sum up the 12-month efficacy of intravitreal 
ranibizumab, aflibercept, bevacizumab and dexametha-
sone implant in treating DME. Overall, our results sup-
port the use of these drugs as effective treatment options 
for the management of DME, demonstrating that signifi-
cant vision amelioration is achievable. The results showed 
an overall increase in visual acuity of approximately +8 
ETDRS letters following 12 months of intravitreal ther-
apy. However, a high variability exists between studies, as 
shown by the large variance in pooled effect size (p 
heterogeneity, <0.001). To elaborate on this matter, 
RCTs and real-life/observational studies were stratified 
into separate analyses. RCTs were calculated to have 
a pooled increase in visual acuity of +8.47 letters (95% 
CI: 7.21–9.72) compared to baseline, and real-life/obser-
vational studies had pooled increase of +7.97 letters (95% 
CI: 6.70–9.24). Overall, no statistically significant differ-
ence in terms of BCVA was detected between RCTs and 
real-life studies and, as expected, we found a high varia-
bility in real-life results. Even when stratified by drug 
classes (anti-VEGF agents and dexamethasone), differ-
ences in 1-year BCVA change between RCTs and real- 
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life/observational studies remain not significant. This is in 
contrast to previous studies reporting that the real-world 
DME treatment outcomes with anti-VEGFs are meaning-
fully worse than those from RCTs. Specifically, patients 
with DME experienced a mean 1-year BCVA gain of 
approximately +5 letters in a clinical setting, while in 
the DRCR.net Protocol T trial, vision improved by 
a mean of +13.3, +9.7 and +11.2 at 1 year for eyes treated 
with aflibercept, bevacizumab and ranibizumab, 
respectively.9,19,80–82
The essential idea in a meta-analysis is that the esti-
mates of the effect from previous studies of interest are 
pooled together, estimating a study-specific true effect. 
The observed heterogeneity in the estimates is attributed 
to between-study heterogeneity in true effects, and within- 
study sampling error. For the above-mentioned reasons, 
we believe that a random-effects approach is the best 
method to be used in our meta-analysis and meta- 
regression.83
When considering the results with dexamethasone 
implant, the visual outcomes surprisingly showed a trend 
to better performance in real-life studies (+1.8 letters) than 
those observed in RCTs. Differences in DME duration and 
the possibility of retreating at an earlier stage in real life, 
as opposed to the fixed treatment regimens required for the 
larger RCT studies (every 6 months or 5 months) may 
explain this difference in results.46,84–88
Mounting evidence from the literature suggests that the 
frequency of anti-VEGF injections has an influence on the 
visual outcome when treating a DME patient.80,81,89,90 Our 
findings reinforce this assumption. Specifically, we found 
a statistically significant correlation between BCVA gain 
and the number of anti-VEGF injections. Each additional 
injection produces +0.88 letter gain at month 12. However, 
these findings are not homogeneous for all anti-VEGF 
drugs.
Aflibercept seems to be the less sensitive agent to the 
frequency of injections (coefficient +0.40 ETDRS letters 
per injection). Conversely, ranibizumab and bevacizumab 
seem to be more dependent on the number of injections 
given per year (bevacizumab coefficient +0.99, ranibizu-
mab coefficient +1.08). This finding may be attributable to 
drug pharmacological properties and to the characteristics 
of the studies included in the analysis. Specifically, the 
variability in the number of injections is narrower in 
aflibercept studies than in those using ranibizumab and 
bevacizumab. This is mostly due to the fact that the 
majority of aflibercept studies use a proactive treatment 
scheduling (fixed or treat and extend) whereas a large 
proportion of the ranibizumab and bevacizumab studies 
apply a PRN approach which implies a larger variability 
in the number of injections. As known, the treatment regi-
men influences the final outcomes.89 In our meta- 
regression, we found a trend to better outcomes when 
employing a fixed treatment regimen. Administrative and 
logistic factors may hinder therapeutic efficacy of PRN 
treatment regimen in a real-life scenario. Difficulty in 
scheduling appointments for treatment and monitoring 
visits is just an example of a real-world factor that may 
result in inferior actual clinical outcomes. A recently pub-
lished comparison of DME trials shows that fixed dosing 
regimens or strict PRN regimens with clear retreatment 
criteria help to maximize the gains in BCVA, leading to 
optimal outcomes for patients.9 In contrast, the results 
from trials with less strict PRN treatment criteria show 
diminished BCVA gains and fewer injections in year 1 
compared with trials with more rigorous regimens.6,9,24,25
When looking for baseline characteristics that may 
influence the outcome, we noted that the 12-month change 
in BCVA negatively correlated with baseline BCVA in 
patients with DME, which is consistent with prior studies 
noting a negative correlation between baseline BCVA and 
long-term BCVA change.91,92 This has been described as 
a “ceiling effect” in which the visual acuity gained by anti- 
VEGF and dexamethasone implant use reaches 
a maximum over the time-course of treatment. Hence, 
patients with higher baseline visual acuity may experience 
a lesser degree of visual acuity gain due to starting with 
a visual acuity closer to the maximum benefit afforded by 
the treatment.93 Our meta-regression also revealed 
a decreasing trend in visual acuity change with increasing 
age. The negative correlation between age and BCVA 
change at 12 months observed is likely a manifestation 
of worsened outcomes at later age of presentation, when 
both the advanced progression of the disease and 
decreased response to treatment may result in inferior 
clinical outcomes. However, the correlation was not sta-
tistically significant which may be on account of the high 
variability between studies.
Strengths and Limitations
The present analysis has the following strengths: it pro-
vides an overview that is exhaustive and representative of 
the different therapeutic approaches used in clinical prac-
tice and in RCTs to manage patients with DME, we used 
a predefined search strategy and two independent 
Clinical Ophthalmology 2021:15                                                                                             submit your manuscript | www.dovepress.com                                                                                                                                                                                                                       
DovePress                                                                                                                         
381






























































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
reviewers conducted data extraction. Moreover, we con-
ducted subgroup and sensitivity analysis. However, some 
important limitations should be noted. The main limitation 
of our meta-analysis is the quality of the included studies. 
Non-randomized studies exhibit a risk of bias. First, the 
heterogeneity among studies was high, possibly due to 
confounding variables as varying sample sizes, study 
designs, DME subtypes and treatment modalities. 
Actually, comparing RCTs with observational studies pre-
disposes bias due to uncontrolled confounding. Moreover, 
this meta-analysis and meta-regression rely on papers 
which are not free from sample selection bias. In addition, 
the meta-analysis was based on aggregate data and not 
patient-level data, so it may be prone to ecological bias. 
Our findings are, consequently, an ecological association, 
based on aggregate measures in a highly selected popula-
tion. They are not a causal association that can directly be 
extrapolated to an individual level. For these reasons, 
caution must be taken in assuming any particular form of 
quantitative relationship, which may change over time and 
with a greater number of studies. Summary estimates 
based on methodologically limited studies should not be 
over-interpreted and it must be noted that the best evidence 
synthesis to explore the impact of effect modifiers in 
a complex evidence network is a network meta-analysis. 
It allows both direct comparisons of interventions within 
randomized controlled trials and indirect comparisons 
across trials based on a common comparator.
Conclusion
In conclusion, the evidence for intravitreal therapy has 
been established in this meta-analysis to be highly 
favorable in the treatment of DME equally in clinical 
trials and real-world clinical settings. Frequent injec-
tions are required to preserve the outcomes of anti- 
VEGF therapy. Increased injection frequency and 
younger age demonstrates a trend with improved 
outcomes.
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